Genzyme, Sanofi Take Aim At Generic Cancer Drug

Law360, New York (August 30, 2013, 6:03 PM EDT) -- Drugmakers Genzyme and Sanofi-Aventis sued three pharmaceutical companies Friday in Delaware federal court, claiming that the companies’ generic drugs will violate Genzyme’s patents for the cancer treatment drug Mobozil.

The complaints, filed in the U.S. District Court for the District of Delaware, allege that Sandoz, Inc., Teva Pharmaceuticals USA, Inc. and India-based Dr. Reddy's Laboratories will infringe Genzyme’s patents if they are allowed to market Plerixafor Injection 20mg/mL, a proposed generic version of Genzyme’s Mobozil. If not enjoined, the defendants' infringement will "substantially and irreparably" harm...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.